Recent Company News

• 11:11 AM ET Aug 24, 2026
  

  Follow-up: StreetAccount Summary - Private company transactions for the week ended 22-Aug

• 09:35 AM ET Aug 24, 2026
  

  StreetAccount Summary - Private company transactions for the week ended 22-Aug

• 02:34 AM ET Aug 24, 2026
  

  China's NMPA to include Pluvicto of Novartis in priority review in PSMA-positive mCRPC (CHF 127.42, 0.00)

• 02:21 PM ET Aug 21, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 23-Aug

• 07:01 PM ET Aug 18, 2026
  

  FDA grants orphan drug designation to iptacopan for treatment of atypical hemolytic uremic syndrome (CHF 125.56, 0.00)

• 12:58 PM ET Aug 14, 2026
  

  FDA publishes CRL for ITM-11 sent to ITM Solucion GmbH (private); receipt previously disclosed by company

• 01:07 AM ET Aug 13, 2026
  

  Pharming Group announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with activated PI3K delta syndrome (APDS) aged 4 years and older (€1.00, 0.00)

• 08:25 PM ET Aug 11, 2026
  

  Laekna's LAE002 (afuresertib) NDA accepted by China NMPA for HR+/HER2- breast cancer (HK$7.28, 0.00)

• 02:01 PM ET Aug 10, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 3-Aug

• 11:38 AM ET Aug 10, 2026
  

  ITM (private) announces receipt of CRL from FDA for ITM-11 (earlier, 10:00ET)